Beneficial effects of GW274150, a novel, potent and selective inhibitor of iNOS activity, in a rodent model of collagen-induced arthritis

European Journal of Pharmacology

Volumn 453, Issue 1, 2002, Pages 119-129

  Cuzzocrea, Salvatore ^a   Chatterjee, Prabal K ^b   Mazzon, Emanuela ^a   McDonald, Michelle C ^b   Dugo, Laura ^a   Di Paola, Rosanna ^a   Serraino, Ivana ^a   Britti, Domenico ^c   Caputi, Achille P ^a   Thiemermann, Christoph ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

Arthritis, collagen induced; GW274150; Nitric oxide (NO) synthase, inducible

Indexed keywords

2 AMINO (1 IMINOETHYLAMINO) 5 THIOHEPTANOIC ACID; 3 NITROTYROSINE; COLLAGEN TYPE 2; FREUND ADJUVANT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; S [2 (1 IMINOETHYLAMINO)ETHYL]HOMOCYSTEINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; ATTENUATION; CHONDROLYSIS; CHRONIC INFLAMMATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MODEL; DISEASE SEVERITY; DRUG EFFECT; DRUG POTENCY; EDEMA; EMULSION; ENZYME ACTIVITY; ENZYME INHIBITION; ERYTHEMA; HINDLIMB; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; KNEE; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROTECTION; PROTEIN FUNCTION; RADIOGRAPHY; STAINING; TISSUE INJURY; TISSUE SECTION; WILD TYPE;

ANIMALS; ARTHRITIS, EXPERIMENTAL; COLLAGEN; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; SULFIDES;

EID: 0037130983     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02338-5     Document Type: Article

References (41)

1. Alderton W., Angell A., Clayton N., Craig C., Dawson J., Frend A., McGill J., Mangel A., Moncada S., Rees D., Russell L., Schwartz S., Waslidge N., Knowles R. GW274150 is a potent, long-acting, highly selective inhibitor of iNOS (NOS-2) with therapeutic potential in post-operative ileus. Acta Physiol. Scand. 167:1999;O-36.
2. Beckman J.S. Oxidative damage and tyrosine nitration from peroxynitrite. Chem. Res. Toxicol. 9:1996;836-844.
3. Brahn E., Banquerigo M.L., Firestein G.S., Boyle D.L., Salzman A.L., Szabó C. Collagen induced arthritis: reversal by mercaptoethylguanidine, a novel antiinflammatory agent with a combined mechanism of action. J. Rheumatol. 25:1998;1785-1793.
4. Crow J.P., Beckman J.S. The role of peroxynitrite in nitric oxide-mediated toxicity. Curr. Top. Microbiol. Immunol. 196:1995;57-73.
5. Cuzzocrea S., Zingarelli B., Gilard E., Hake P., Salzman A.L., Szabò C. Protective effect of melatonin in carrageenan-induced models of local inflammation. J. Pineal Res. 23:1997;106-116.
6. Cuzzocrea S., Zingarelli B., Gilard E., Hake P., Salzman A.L., Szabò C. Anti-inflammatory effects of mercaptoethylguanidine, a combined inhibitor of nitric oxide synthase and peroxynitrite scavenger, in carrageenan-induced models of inflammation. Free Radic. Biol. Med. 24:1998;450-459.
7. Cuzzocrea S., Caputi A.P., Zingarelli B. Peroxynitrite-mediated DNA strand breakage activates poly(ADP-ribose) synthetase and causes cellular energy depletion in carrageenan-induced pleurisy. Immunology. 93:1998;96-101.
8. Cuzzocrea S., Costantino G., Mazzon E., Caputi A.P. Beneficial effects of raxofelast (IRFI 016), a new hydrophilic vitamin E-like antioxidant, in carrageenan-induced pleurisy. Br. J. Pharmacol. 126:1999;407-414.
9. Cuzzocrea S., Mazzon E., Calabro G., Dugo L., De Sarro A., van De Loo F.A., Caputi A.P. Inducible nitric oxide synthase-knockout mice exhibit resistance to pleurisy and lung injury caused by carrageenan. Am. J. Respir. Crit. Care Med. 162:2000;1859-1866.
10. Cuzzocrea S., McDonald M.C., Mazzon E., Siriwardena D., Serraino I., Dugo L., Britti D., Mazzullo G., Caputi A.P., Thiemermann C. Calpain inhibitor I reduces the development of acute and chronic inflammation. Am. J. Pathol. 157:2000;2065-2079.
11. Cuzzocrea S., Riley D.P., Caputi A.P., Salvemini D. Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol. Rev. 53:2001;135-159.
12. Eiserich J.P., Cross C.E., Jones A.D., Halliwell B., van der Vliet A. Formation of nitrating and chlorinating species by reaction of nitrite with hypochlorous acid. A novel mechanism for nitric oxide-mediated protein modification. J. Biol. Chem. 271:1996;19199-19208.
13. Eiserich J.P., Hristova M., Cross C.E., Jones A.D., Freeman B.A., Halliwell B., van der Vliet A. Formation of nitric oxide derivatives catalysed by myeloperoxydase in neutrophils. Nature. 391:1998;393-397.
14. Farrell A.J., Blake D.R., Palmer R.M.J., Moncada S. Increased concentration of nitrite in synovial fluid and serum suggest increased nitric oxide synthesis in rheumatic diseases. Ann. Rheum. Dis. 51:1992;1219-1222.
15. Goldblum S.E., Wu K.M., Jay M. Lung myeloperoxydase as a measure of pulmonary leukostasis in rabbits. J. Appl. Physiol. 59:1985;1978-1985.
16. Harris E.D. Jr. Rheumatoid arthritis: pathophysiology and implication for therapy. N. Engl. J. Med. 322:1990;1277-1282.
17. Heller B., Wang Z.Q., Wagner E.F., Radons J., Burkle A., Fehsel K., Burkart V., Kolb H. Inactivation of the poly(ADP-ribose) polymerase gene affects oxygen radical and nitric oxide toxicity in islet cells. J. Biol. Chem. 270:1995;11176-11180.
18. Holmdahl R.M., Andersson T.J., Goldschmidt K., Gustafsson L., Jansson L., Mo J.A. Type II collagen autoimmunity in animals and provocations leading to arthritis. Immunol. Rev. 118:1990;193-232.
19. Ialenti A., Moncada S., Di Rosa M. Modulation of adjuvant arthritis by endogenous nitric oxide. Br. J. Pharmacol. 110:1993;701-706.
20. Küpper J.H., van Gool L., Muller M., Burkle A. Detection of poly(ADP-ribose) polymerase and its reaction product poly(ADP-ribose) by immunocytochemistry. Histochem. J. 28:1996;391-395.
21. MacMicking J.D., Nathan C., Hom G., Chartrain N., Fletcher D.S., Trumbauer M., Stevens K., Xie Q.W., Sokol K., Hutchinson N. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell. 81:1995;641-650.
22. McCartney-Francis N., Allen J.B., Mizel D.E., Albina J.E., Xie Q.W., Nathan C.F., Wahl S.M. Suppression of arthritis by an inhibitor of nitric oxide synthase. J. Exp. Med. 178:1993;749-754.
23. McCartney-Francis N., Song X., Mizel D.E., Whal S.M. Selective inhibition of inducible nitric oxide synthase exacerbates erosive joint disease. J. Immunol. 166:2001;2734-2740.
24. McCord J. Oxygen-derived free radicals. New Horizons. 1:1993;70-76.
25. McInnes I.B., Leung B., Wei X.-Q., Gemmell C.C., Liew F.Y. Septic arthritis following Staphylococcus aureus infection in mice lacking inducible nitric oxide synthase. J. Immunol. 160:1998;308-315.
26. Moncada S., Palmer R.M.J., Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43:1991;109-141.
27. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J. 6:1992;3051-3064.
28. Novelli G.P. Oxygen-radicals in experimental shock: effects of spin-trapping nitrones in ameliorating shock pathophysiology. Crit. Care Med. 20:1992;499-507.
29. Ohkawa H., Ohishi N., Yagi K. Assay for peroxidases in animal tissues by thiobabituric acid reaction. Anal. Biochem. 95:1979;351-358.
30. Oyanagui Y. Nitric oxide and superoxide radical are involved in both initiation and development of adjuvant arthritis in rats. Life Sci. 54:1994;PL285-PL289.
31. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., Ott S.M., Recker R.R. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 2:1987;595-610.
32. Pelletier J.P., Jovanovic D.V., Lascau-Coman V., Fernandes J.C., Manning P.T., Connor J.R., Currie M.G., Martel-Pelletier J. Selective inhibition of inducible nitric oxide synthase reduces progression of experimental osteoarthritis in vivo: possible link with the reduction in chondrocyte apoptosis and caspase 3 level. Arthritis Rheum. 43:2000;1290-1299.
33. Salvemini D., Wang Z.Q., Wyatt P., Bourdon D.M., Marino M.H., Manning P.T., Currie M.G. Nitric oxide: a key mediator in the early and late phase of carrageenan-induced rat paw inflammation. Br. J. Pharmacol. 118:1996;829-838.
34. Salvemini D., Wang Z.Q., Stern M.K., Currie M.G., Misko T.P. Peroxynitrite decomposition catalysts: therapeutics for peroxynitrite-mediated pathology. Proc. Natl. Acad. Sci. U. S. A. 95:1998;2659-2663.
35. Stuart J.M., Townes A.S., Kang A.H. Collagen autoimmune arthritis. Annu. Rev. Immunol. 2:1984;199-218.
36. Szabò C. Alterations in the production of nitric oxide in various forms of circulatory shock. New Horizons. 3:1995;3-32.
37. Szabò C., Dawson V.L. Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion. Trends Pharmacol. Sci. 19:1998;287-298.
38. Szabò C., Virag L., Cuzzocrea S., Scott G.S., Hake P., O'Connor M., Zingarelli B., Ma Y., Hirsch R., Boiovin G.P., Salzman A.L., Kun E. Protection against peroxynitrite-induced fibroblast injury and arthritis development by induction of poly(ADP-ribose) synthetase. Proc. Natl. Acad. Sci. U. S. A. 95:1998;3867-3872.
39. Thiemermann C., Rutten H., Wu C.C., Vane J.R. The multiple organ dysfunction syndrome caused by endotoxin in the rat: attenuation of liver dysfunction by inhibitors of nitric oxide synthase. Br. J. Pharmacol. 116:1995;2845-2851.
40. Van de Loo F.A.J., Kuiper S., van Enckevort F.H.J., Arntz O.J., van den Berg W.B. Interleukin-6 ameliorates cartilage destruction during experimental arthritis: a study in interleukin-6-deficient mice. Am. J. Pathol. 151:1997;177-191.
41. Veihelmann A., Landes J., Hofbauer A., Dorger M., Refior H.J., Messmer K., Krombach F. Exacerbation of antigen-induced arthritis in inducible nitric oxide synthase-deficient mice. Arthritis Rheum. 44:2001;1420-1427.